ARS Pharmaceuticals, Inc. (SPRY) ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call Transcript

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call August 12, 2024 8:00 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - President and CEO Eric Karas - Chief Commercial Officer Conference Call Participants Tim Lugo - William Blair Ryan Deschner - Raymond James Roanna Ruiz - Leerink Partners Julian Harrison - BTIG Operator Good day and welcome to the ARS Pharmaceuticals' neffy (epinephrine nasal spray) ...